Association of CYP24A1 with survival and drug resistance in clinical cancer patients: a meta-analysis

Rui Zeng,Hua Li,Lingyan Jia,Sau Har Lee,Rilei Jiang,Yujia Zhang,Xudong Hu,Tingjie Ye,Xiaoling Wang,Xiaofeng Yan,Yanlin Lu,Zhumei Sun,Jiatuo Xu,Wei Xu
DOI: https://doi.org/10.1186/s12885-022-10369-x
IF: 4.638
2022-12-17
BMC Cancer
Abstract:Acquired chemo-drug resistance constantly led to the failure of chemotherapy for malignant cancers, consequently causing cancer relapse. Hence, identifying the biomarker of drug resistance is vital to improve the treatment efficacy in cancer. The clinical prognostic value of CYP24A1 remains inconclusive, hence we aim to evaluate the association between CYP24A1 and the drug resistance in cancer patients through a meta-analysis approach.
oncology
What problem does this paper attempt to address?